MP: Intelligent biofeedback treatment for migraine headaches

1 in 7 people in the world suffer from migraine and it is the most disabling disease in people under 50. Researchers at NTNU and St.Olavs Hospital have since 2015 developed a new method for reducing migraines without medication. Using wireless sensors and a digital therapist, patients can perform effective treatment at home instead of going to the hospital. The treatment is based on the principle of biofeedback, which is a well-established treatment and has a proven effect on headaches and migraines. Unfortunately, there has been little available in Norway and it usually requires large stationary equipment. We have now developed and created biofeedback in a simple and affordable format. The developed treatment is research-based and several clinical studies have been conducted on adults and children to investigate the ease of use and efficacy. The results have been positive and the product is, therefore, undergoing further research and development. The goal is to offer effective treatment with good documented efficacy and safety, which is easy to use and cheaper than today's alternatives. It is important for the patient group to have better access to non-drug solutions because many people suffer from side effects, have limited access to treatment and experience limited effect from today's offerings. The commercialization project will explore international market opportunities for the product. This is important to understand the barriers that exist in the markets and what requirements the customer and other authorities have. The project will also strengthen the intellectual property rights of the product and ensure enhanced competitive advantage in an international context.

The project has revealed a strong market acceptance for our novel migraine treatment in the Germany market, a strategy for the regulatory pathway into the US and a filed patent for IP protection of the invention for increased competitiveness. The milestone project has therefore had a significant impact on the commercialisation of Nordic Brain Tech's preventive migraine treatment. From our conducted market research, regulatory pathway and filed patent, our business plan has now decreased market risk, which is compelling for investors and therefore increases our chances to raise private capital. Moreover, increased chances for a successful commercialisation means that 1 billion people living with migraines worldwide can get access to an affordable and efficient treatment that they have not available today. This will decrease health related costs to migraines and most importantly increase the quality of life of people living with migraine.